Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update - New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy with Oral Fadraciclib -- First Patients Enrolled in Oral Fadraciclib Phase 2 Proof of...

Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update – On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support...

Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions - Patient Pharmacodynamic Data Show Decrease in CDKN2A, CDKN2B, and PRMT5 Protein Levels - - A Squamous Non-Small Cell Lung Cancer Patient with CDKN2B Deletion Achieved Marked Tumor Shrinkage...

Advanced Dermatology and Cosmetic Surgery Provides Breast Cancer Patients and Survivors with Free Skin Cancer Screenings for Breast Cancer Awareness Month MAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE) -- In honor of Breast Cancer Awareness Month, Advanced Dermatology and Cosmetic Surgery announces it will offer complimentary skin cancer screenings...